Reduction of hippocampal IL-6 levels in LPS-injected rats following acute exendin-4 treatment.

Preclinical evidence on the role of glucagon-like peptide-1 receptor (GLP-1r) agonists in the brain led to an increased interest in repurposing these compounds as a therapy for central nervous system (CNS) disorders and associated comorbidities. We aimed to investigate the neuroprotective effects of acute treatment with exendin (EX)-4, a GLP-1r agonist, in an animal model of inflammation. We evaluated the effect of different doses of EX-4 on inflammatory, neurotrophic, and oxidative stress parameters in the hippocampus and serum of lipopolysaccharide (LPS)-injected animals.

Anhedonic-like behavior correlates with IFNγ serum levels in a two-hit model of depression.

Stress is implicated in the etiology of major depressive disorder (MDD) and leads to the activation of proinflammatory pathways, which are recognized to induce depressive symptoms. For instance, depression is commonly observed in patients with hepatitis C and cancer under IFN therapy, and high levels of inflammatory cytokines are described in the serum of individuals with MDD - which indicate a multi-system aspect of psychiatric disorders. Thus, we evaluated the effects of a two-hit model of depression on peripheral and CNS inflammatory, neurotrophic, and oxidative stress parameters and behavior.